ERBB2 and metastatic neoplasm: Potential additional benefit of the utilisation of other therapeutic approaches is currently undergoing clinical investigation, such as the synergistic combination of endocrine therapy plus dual HER2-targeted therapy and a CDK4/6 inhibitor in patients with ER+/HER2+ metastatic disease (Krause et al. 2019).